Morphocell rounds out Series A at $50 million USD to accelerate liver regeneration tech
Montreal-based biotech Morphocell Technologies, which works to regenerate tissues and organs for patients with liver failure, has rounded out its Series A at $50 million USD ($70 million CAD) thanks to new commitments from Investissement Québec and Italy’s CDP Venture Capital. The funding will help Morphocell expand its manufacturing capacity, lay the foundation for future…
